CYP51A1 and Chagas disease: However, low parasitological cure rates that were observed (20–30%) during clinical testing of anti-fungal drugs targeting sterol 14α-demethylase (posaconazole and ravuconazole prodrug E1224) in Chagas disease patients have lessened enthusiasm for further work on repurposed CYP51 inhibitors as single agents [61, 62].